在符合全球疫苗免疫联盟(Gavi)资助条件的国家中接种单剂次人乳头瘤病毒(HPV)疫苗的健康与经济收益
本研究采用三层混合模型模拟乌干达单剂次HPV疫苗接种(假设对HPV-16/18感染 efficacy 80%,三种抗体衰减情景)与不接种及两剂次接种(假设终身100% efficacy)的长期健康经济影响。结果显示单剂次接种较不接种可节省成本;若保护持久且覆盖率更高,单剂次较两剂次具成本效果。
要点
- 单剂次HPV疫苗接种较不接种可节省成本。
- 接种40年后,单剂次(覆盖率70%)避免15-16%宫颈癌病例,两剂次避免21%。
- 若单剂次保护持久且覆盖率可达90%,则较两剂次更具成本效果。
核心结论
- 单剂次HPV疫苗接种较不接种可节省成本;若保护持久且能实现更高覆盖率,则较两剂次接种具成本效果。
研究设计与样本
- 采用三层混合建模方法,整合HPV传播、宫颈癌发生和人口统计学,模拟乌干达单剂次HPV疫苗接种(假设对HPV-16/18感染 efficacy 80%,三种抗体衰减情景)和两剂次接种(假设终身100% efficacy)。
主要发现
- 单剂次HPV疫苗接种需大量前期投入,但计入未来避免癌症的成本抵消后,较不接种可节省成本。
- 启动常规接种40年后,单剂次接种在覆盖率70%时避免15-16%宫颈癌病例,两剂次避免21%,但单剂次仅需一半前期经济投入。
- 两剂次接种具良好成本效果,但若单剂次接种可实现更高覆盖率(90% vs. 70%)且不衰减,则单剂次可能更优。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although guidelines for prophylactic human papillomavirus (HPV) vaccination recommend two doses for girls ages 9-14 years, several studies have demonstrated similar protection with one dose. Our objective was to evaluate the long-term health and economic impacts of routine one-dose HPV vaccination compared to (1) no vaccination and (2) two-dose HPV vaccination in a low-income country. METHODS: We used a three-tiered hybrid modeling approach that captured HPV transmission, cervical carcinogenesis, and population demographics to project long-term health and economic outcomes associated with one-dose HPV vaccination (assuming 80% efficacy against HPV-16/18 infections under three waning scenarios) and two-dose HPV vaccination (assuming 100% efficacy over the lifetime) in Uganda. Costs included the vaccine program (dosage and delivery) costs over a 10-year period and cervical cancer costs over the lifetimes of the current population of Ugandan women. Health outcomes included number of cervical cancer cases and disability-adjusted life years (DALYs). Incremental cost-effectiveness ratios (i.e., cost per DALY averted) were calculated and compared against the Ugandan per-capita gross domestic product. RESULTS: Routine one-dose HPV vaccination of 9-year-old girls required substantial upfront investment but was cost-saving compared to no vaccination when accounting for the cost-offsets from future cancers averted. Forty years after initiating routine vaccination and depending on assumptions of vaccine waning, one-dose HPV vaccination with equivalent coverage (70%) averted 15-16% of cervical cancer cases versus 21% with two-dose vaccination but required only half the upfront economic investment. Vaccination with two doses had an attractive cost-effectiveness profile except if one-dose vaccination enabled higher coverage (90% vs. 70%) and did not wane. CONCLUSIONS: One-dose HPV vaccination resulted in cost-savings compared to no vaccination and could be cost-effective compared to two-dose vaccination if protection is longstanding and higher coverage can be achieved.
引用
- Burger EA, Campos NG, Sy S, et al. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country. Vaccine. 2018. PMID: 29807710. doi:10.1016/j.vaccine.2018.04.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。